Oncology
2 drugs are in development for Generalized Myasthenia Gravis.
- Companies
- 2
- Clinical trials
- 26
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Generalized Myasthenia Gravis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| telitacicept | Vor Biopharma Inc. (VOR) |
Phase 2(1)
| Drug | Company |
|---|---|
| Efgartigimod IV | ARGENX SE (ARGX) |
About this indication
Generalized Myasthenia Gravis context
Oncology·MeSH: Myasthenia Gravis (D009157)
Narrower concept of MeSH descriptor Myasthenia Gravis
Incidence
1.7 / 100K/yr
Frequently asked questions
How many drugs are in development for Generalized Myasthenia Gravis?
BioSniper tracks 2 drugs in development for Generalized Myasthenia Gravis across 2 companies.
How many clinical trials target Generalized Myasthenia Gravis?
There are 26 clinical trials targeting Generalized Myasthenia Gravis tracked by BioSniper.